در مبتلايان به هليكوباكتر پيلوري OBAM - OBAT مقايسه دو رژيم

Comparing two regimens of OBAT and OBAM for helicobacter pylori eradication

Background: Helicobacter pylori (HP) is a spiral gram negative bacillus. It is a prevalent worldwide pathogen especially in developing countries. It is a well-defined pathogen in the pathogenesis of peptic ulcer, dyspepsia, and adenocarcinoma of stomach, however, researchersʹ attempts failed to develop an effective vaccine. Thus the eradication of HP is of utmost importance. Materials and methods: 60 patients with dyspepsia have undertaken esophagogastroduodenoscopy and antrum biopsy, all of whom revealed to be HP positive. They were randomly assigned to two groups and received their therapeutic regimens for two weeks. The first group received omeprazol+bismoth+amoxycillin+metronidazol (OBAM), however the second group was given omeprazol+bismoth+amoxycillin+Thyme oil (OBAT). Three months later, esophagogastroduodenoscopy was performed. Results: Twenty-five patients in OBAM and 33 in OBAT have finished their therapy course. We have not found significant difference regarding the eradication of HP (16% in OBAM and 17.4% in OBAT group, respectively), recovery of dyspepsia, and recovery of chronic gastritis between the groups. Meanwhile, there was no significant difference in smoking during the therapy. Conclusion: With respect to the high level of antibiotic resistance to HP specially in developing countries, we suggest antibiogram for HP prior to treatment.